Nanoparticle-mediated drug delivery system for coronary artery disease

Tetsuya Matoba; Jun Ichiro Koga; Kaku Nakano; Kensuke Egashira

doi:10.2745/dds.30.299

Nanoparticle-mediated drug delivery system for coronary artery disease

Tetsuya Matoba, Jun Ichiro Koga, Kaku Nakano, Kensuke Egashira

Angiocardiology

Research output: Contribution to journal › Review article › peer-review

Abstract

Coronary artery disease including acute myocardial infarction is a significant concern in cardiovascular medicine, because of their high acute mortality and morbidity causing lethal heart failure. Atherosclerotic plaque destabilization and rupture are central pathogenesis of acute myocardial infarction, whereas myocardial ischemia-reperfusion injury is another adverse phenomenon in the heart undergoing early reperfusion therapy for acute myocardial infarction. There are un-met needs for these pathological conditions to be overcome by the use of nanoparticle-mediated drug delivery system (DDS). We provide overview of the mechanistic background for the use of DDS and the efficacy of nano-medicine in preclinical disease models.

Original language	English
Pages (from-to)	299-308
Number of pages	10
Journal	Drug Delivery System
Volume	30
Issue number	4
DOIs	https://doi.org/10.2745/dds.30.299
Publication status	Published - Dec 25 2015

All Science Journal Classification (ASJC) codes

Pharmaceutical Science

Access to Document

10.2745/dds.30.299

Cite this

@article{2a05b6d239a547e7aa982011a9697ded,

title = "Nanoparticle-mediated drug delivery system for coronary artery disease",

abstract = "Coronary artery disease including acute myocardial infarction is a significant concern in cardiovascular medicine, because of their high acute mortality and morbidity causing lethal heart failure. Atherosclerotic plaque destabilization and rupture are central pathogenesis of acute myocardial infarction, whereas myocardial ischemia-reperfusion injury is another adverse phenomenon in the heart undergoing early reperfusion therapy for acute myocardial infarction. There are un-met needs for these pathological conditions to be overcome by the use of nanoparticle-mediated drug delivery system (DDS). We provide overview of the mechanistic background for the use of DDS and the efficacy of nano-medicine in preclinical disease models.",

author = "Tetsuya Matoba and Koga, {Jun Ichiro} and Kaku Nakano and Kensuke Egashira",

year = "2015",

month = dec,

day = "25",

doi = "10.2745/dds.30.299",

language = "English",

volume = "30",

pages = "299--308",

journal = "Drug Delivery System",

issn = "0913-5006",

publisher = "Japan Society of Drug Delivery System",

number = "4",

}

TY - JOUR

T1 - Nanoparticle-mediated drug delivery system for coronary artery disease

AU - Matoba, Tetsuya

AU - Koga, Jun Ichiro

AU - Nakano, Kaku

AU - Egashira, Kensuke

PY - 2015/12/25

Y1 - 2015/12/25

N2 - Coronary artery disease including acute myocardial infarction is a significant concern in cardiovascular medicine, because of their high acute mortality and morbidity causing lethal heart failure. Atherosclerotic plaque destabilization and rupture are central pathogenesis of acute myocardial infarction, whereas myocardial ischemia-reperfusion injury is another adverse phenomenon in the heart undergoing early reperfusion therapy for acute myocardial infarction. There are un-met needs for these pathological conditions to be overcome by the use of nanoparticle-mediated drug delivery system (DDS). We provide overview of the mechanistic background for the use of DDS and the efficacy of nano-medicine in preclinical disease models.

AB - Coronary artery disease including acute myocardial infarction is a significant concern in cardiovascular medicine, because of their high acute mortality and morbidity causing lethal heart failure. Atherosclerotic plaque destabilization and rupture are central pathogenesis of acute myocardial infarction, whereas myocardial ischemia-reperfusion injury is another adverse phenomenon in the heart undergoing early reperfusion therapy for acute myocardial infarction. There are un-met needs for these pathological conditions to be overcome by the use of nanoparticle-mediated drug delivery system (DDS). We provide overview of the mechanistic background for the use of DDS and the efficacy of nano-medicine in preclinical disease models.

UR - http://www.scopus.com/inward/record.url?scp=84951789812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951789812&partnerID=8YFLogxK

U2 - 10.2745/dds.30.299

DO - 10.2745/dds.30.299

M3 - Review article

AN - SCOPUS:84951789812

SN - 0913-5006

VL - 30

SP - 299

EP - 308

JO - Drug Delivery System

JF - Drug Delivery System

IS - 4

ER -

Nanoparticle-mediated drug delivery system for coronary artery disease

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this